中文
中文
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士
为了病患而驱动的创新
Patient-first cell therapy innovation. 
 

首页产品及临床产品管线
产品管线
产品管线
PIPELINES
中国 全球 美国
TIL
Product
Candidate
Product
Candidate
Indication(s)
Preclinical
IND-Enabling
Phase 1
Phase 2
Pivotal
Pivotal
 
HW-101
HW-101
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4 FDA RMAT designation
View trial
HW-01
HW-01
Melanoma (post-anti-PD-1)
C-145-04 Study, Cohorts 1 & 2 FDA BTD
View trial
HW-10
HW-10
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial
HW-101
HW-101
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial
HW-01
HW-01
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
C144-01 Study, Cohorts 2 & 4
C144-01 Study, Cohorts 2 & 4
View trial
HW-10
HW-10
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial
HW-10
HW-10
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial
HW-10
HW-10
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial
HW-101
HW-101
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial
HW-01
HW-01
Melanoma (post-anti-PD-1)
C144-01 Study, Cohorts 2 & 4
View trial

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

 粤ICP备20056630号 Powered by vancheer
联系我们
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

 粤ICP备20056630号 Powered by vancheer